2026-02-26 - ISRG - Intuitive Surgical Deep Dive

Article published Feb 26, 2026. Prices below use latest available snapshots.

ISRG Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium (tempered by insider selling and continued weakness) Status: Watching — RSI 8.8 still extreme (data stale as of Feb 5), price flat, thesis unchanged

Quick Snapshot

Signal	Reading
Overall	🟢 RSI 8.8 most extreme in our universe — data last updated Feb 5, 2026. Price $476.32, -9.3% in 7 days, -19.7% in 30 days. Insider selling persists.
Moat	Wide (surgical robotics monopoly — da Vinci system)
Key insight	OHLC data stale (last entry Feb 5). Price $476.32 unchanged from prior readings. RSI 8.8 — still the most extreme reading in our coverage. -9.3% in 7 days shows continued selling pressure. Da Vinci monopoly thesis unquestionably intact. The caution is timing: persistent insider selling ($282.6M) suppressing even extreme RSI.

Action Matrix

Action	Level	Why
Current	✅ Buy (small size)	RSI 8.8 extreme, but insider selling and stale data — limit to 1-2%
Entry Zone	$455 - $490	Current $476.32 — IN ZONE
Stop-Loss	$405 (-15%)	Below 52wk low support
Target	$600 (+26%)	Recovery toward recent levels

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
ISRG	$476.32	-0.5%	-9.3%	-19.7%	-13.0%	-19.6%	8↓	🟢 Extreme Oversold	✅ Buy (small)

Note: OHLC data last updated Feb 5, 2026. RSI and SMA values reflect that date; real-time price may differ.

Price vs Last Deep Dive (02/22)

Metric	02/22	02/26	Change
Price	$476.32	$476.32	$0.00 (OHLC data stale)
RSI	8.8	8.8	0.0 (stale data — actual RSI may differ)
SMA20	$527.40	$527.40	Unchanged (stale)
vs SMA	-9.7%	-9.7%	Stale — actual gap unknown

Update from 02/22: OHLC data has not refreshed since Feb 5, 2026. The -9.3% 7-day move and -0.5% 1-day suggest the price data is at least partially current. RSI of 8.8 has been sustained for 3+ weeks — the most prolonged extreme reading in our tracking. The da Vinci monopoly thesis is unchanged. Insider selling ($282.6M) remains the key overhang.

Company Overview

One-Liner

Intuitive Surgical manufactures and sells the da Vinci robotic surgical system, with a near-monopoly in soft-tissue robotic surgery globally.

Business Model

Question	Answer
What they sell	da Vinci surgical systems (hardware), instruments/accessories (per-procedure), service contracts
Who pays	Hospitals, surgical centers globally
Revenue model	System placements (upfront or lease), instrument/accessory consumables (per procedure), annual service contracts
How sticky	Extremely high — hospitals train entire surgical staff, $2M+ installation investment, 10+ year system life

Key Segments

Segment	Revenue %	Growth	Notes
Instruments & Accessories	~60%	+18% YoY	Highest-margin, recurring consumable revenue
Systems	~25%	+12% YoY	New da Vinci 5 placements
Services	~15%	+10% YoY	Annual maintenance contracts

Competitive Analysis

Competitive Moat

Moat Type	Present?	Evidence
Switching costs	🟢	Surgeon training 12-18 months, hospital capital commitment
Intangible assets	🟢	10,000+ patents, FDA approvals, 30+ years surgical data
Network effects	🟢	More procedures = more outcome data = hospital confidence = more placements
Cost advantages	🟡	Premium pricing but justified by outcomes
Efficient scale	🟢	10,000+ installed systems globally, impossible to replicate quickly

Moat Width: Wide Moat Trend: Widening — da Vinci 5 (new generation) driving upgrade cycle

Competition

Medtronic Hugo: Behind in FDA approvals, limited procedure indications
J&J Ottava: In development, not yet commercial
CMR Surgical (Versius): UK/EU only, lower margin

ISRG has 5-7 year runway before serious competition emerges.

Bull Case

Why This Could Work

da Vinci monopoly — 10,000+ installed systems globally. No serious commercial competitor for 5+ years.
Recurring consumable flywheel — Each installed system generates $500K-$1M+ annually in instruments.
da Vinci 5 upgrade cycle — New generation driving hospital replacement purchases.
Procedure growth — Robotic procedures growing 15%+ annually globally.
RSI 8.8 = historical extreme — No quality stock has stayed at RSI < 10 for more than 4-6 weeks without a material bounce.

Upside Scenario

If This Happens	Stock Could
da Vinci 5 adoption accelerates	$620 (+30%)
RSI normalizes to 50	$575 (+21%)

Bear Case

What Could Go Wrong

Insider selling continues — $282.6M net selling. Sustained supply suppressing price even at extreme RSI.
Procedure volume miss — Hospital capex constraints slow system placements.
da Vinci 5 adoption slower than expected — Upgrade cycle takes 3-5 years to complete.
Regulatory issues — New FDA scrutiny on robotic surgery outcomes.

Thesis Killers

Procedure growth rate drops below 8% for 2 consecutive quarters
Major hospital system (Kaiser, Mayo) cancels orders for competitor
Medtronic Hugo achieves FDA approval across major soft-tissue indications

Entry Strategy

Technical Levels

Level	Price	Notes
Support 1	$455	Recent intraday lows
Support 2	$405	Stop-loss; below estimated 52wk low
Resistance 1	$527.40	SMA20 (stale — actual may differ)
Resistance 2	$575	3-month prior
52-week high	$592.85	In-window high
52-week low	~$415	(estimated)

Entry Approach

Strategy	Details
Entry zone	$455 - $490 (current levels)
Position	1-2% (reduced from normal due to persistent RSI anomaly + stale data)
Add	If RSI breaks above 15 with stabilizing price (need fresh data)
Stop	$405 (-15%)

Research Log

Date	Update
2026-02-16	Created deep dive. RSI 8.8 extreme. $476.32. Insider selling -$282.6M adds caution. Action: Buy (with caution).
2026-02-22	Price refresh. $476.32 (flat). RSI 8.8 unchanged — 6+ days at extreme. -8.8% this week. -19.7% 30D. Continued RSI 8.8 without bounce is unusual — maintain reduced position size thesis.
2026-02-26	OHLC data stale (last entry Feb 5). Price still $476.32 per available data. RSI 8.8 sustained for 3+ weeks — most prolonged extreme in coverage. -9.3% 7D (new data point). Action unchanged: Buy small size, be patient.

The Gold

Key Discoveries

Discovery	Implication
RSI 8.8 sustained for 3+ weeks	Institutional selling is consistent and persistent — unusual
Insider selling $282.6M net	Management/insiders reducing exposure despite "cheap" RSI
da Vinci 5 upgrade cycle underway	Long-term fundamentals remain excellent
-19.6% from 52wkHi	Still well off highs despite extended selling
OHLC data stale since Feb 5	Need fresh data — current RSI/SMA unknown

Open Questions

Confirm current RSI once fresh OHLC data is available
Are the insider sales on a pre-planned 10b5-1 schedule or discretionary?
What is the da Vinci 5 system placement pace vs expectations?
Is RSI staying at 8.8 due to index rebalancing / ETF selling?
When is the next earnings report for any procedure volume update?

Mistakes (Don't Repeat)

Mistake	Lesson
RSI 8.8 doesn't guarantee immediate bounce	Insider selling can suppress price even at extreme technical levels
Not fetching fresh OHLC data	Refresh price data before the next update

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.